Drug Type Small molecule drug |
Synonyms 6-(4-(4-(2,3-Dichlorophenyl)-piperazin-1-yl)-butoxy)-2H-benzo(b)(1,4)oxazin-3(4H)-one, Brilaroxazine Hydrochloride, RP 5000 + [3] |
Mechanism 5-HT1A receptor partial agonists(Serotonin 1a (5-HT1a) receptor partial agonists), 5-HT2A receptor partial agonists(Serotonin 2a (5-HT2a) receptor partial agonists), 5-HT6 receptor antagonists(Serotonin 6 (5-HT6) receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC22H25Cl2N3O3 |
InChIKeyPMKMNTBZJOXTJW-UHFFFAOYSA-N |
CAS Registry1239729-06-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Brilaroxazine | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Schizophrenia | Phase 3 | US | 24 Jan 2022 | |
Acute schizophrenia | Phase 2 | US | 01 Dec 2011 | |
Acute schizophrenia | Phase 2 | IN | 01 Dec 2011 | |
Acute schizophrenia | Phase 2 | MY | 01 Dec 2011 | |
Acute schizophrenia | Phase 2 | MD | 01 Dec 2011 | |
Acute schizophrenia | Phase 2 | PH | 01 Dec 2011 | |
Schizoaffective disorder | Phase 2 | US | 01 Dec 2011 | |
Schizoaffective disorder | Phase 2 | IN | 01 Dec 2011 | |
Schizoaffective disorder | Phase 2 | MY | 01 Dec 2011 | |
Schizoaffective disorder | Phase 2 | MD | 01 Dec 2011 |
Phase 3 | - | dukapmwyzc(hizfsodclb) = ljyfedgbop wepnwfdjuc (lscianjcfs ) Met | Positive | 30 Oct 2023 | |||
Placebo | dukapmwyzc(hizfsodclb) = clftzoqevg wepnwfdjuc (lscianjcfs ) Met | ||||||
Phase 2 | 234 | placebo | ctbnxymjqu(kwxxnyvqnx) = uzgzfxeuik frdsazqbcc (hkozythgnh, lfpyzeydun - qpycbeeeoh) View more | - | 26 Jan 2015 |